IDEAYA Biosciences Announces Updated Clinical Results for IDE849 and Plans for Phase 3 Registrational Trials

IDEAYA Biosciences, Inc. announced updated clinical results for its investigational antibody-drug conjugate IDE849, showing promising anti-tumor activity in patients with relapsed small cell lung cancer and neuroendocrine carcinomas. The company plans to initiate two global Phase 3 registrational trials for IDE849 following successful discussions with the U.S. FDA. IDEAYA is also considering a Phase 3 study design for first-line ES-SCLC while continuing to gather data from ongoing clinical combinations.